Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan.
Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen (Zhongshan) University, Guangzhou, Guangdong.
Int J Surg. 2024 Sep 1;110(9):5641-5651. doi: 10.1097/JS9.0000000000001675.
Most bladder cancers are nonmuscle invasive bladder cancer (NMIBC), and transurethral resection of bladder tumors (TURBT) is the standard treatment. However, postoperative recurrence remains a significant challenge, and the influence of bladder tumor location on prognosis is still unclear. This study aims to investigate how tumor location affects the prognosis of NMIBC patients undergoing TURBT and to identify the optimal surgical approach.
A multicenter study was conducted, which included Chinese NMIBC data from 15 hospitals (1996-2019) and data from 17 registries of the Surveillance, Epidemiology, and End Results database (SEER) (2000-2020). Patients initially diagnosed with NMIBC and undergoing TURBT or partial cystectomy were analyzed, with cases lost to follow-up or with missing data excluded. The study investigated the overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) among patients with different tumor locations. Kaplan-Meier, Cox regression, and propensity score matching methods were employed to explore the association between tumor location and prognosis. Stratified populations were analyzed to minimize bias.
This study included 118 477 NMIBC patients and highlighted tumor location as a crucial factor impacting post-TURBT prognosis. Both anterior wall and dome tumors independently predicted adverse outcomes in two cohorts. For anterior wall tumors, the Chinese cohort showed hazard ratios (HR) for OS of 4.35 ( P <0.0001); RFS of 2.21 ( P <0.0001); SEER cohort OS HR of 1.10 ( P =0.0001); DSS HR of 1.13 ( P =0.0183). Dome tumors displayed similar trends [Chinese NMIBC cohort OS HR of 7.91 ( P <0.0001); RFS HR of 2.12 ( P <0.0001); SEER OS HR of 1.05 ( P =0.0087); DSS HR of 1.14 ( P =0.0006)]. Partial cystectomy significantly improved the survival of dome tumor patients compared to standard TURBT treatment ( P <0.01).
This study reveals the significant impact of tumor location in NMIBC patients on the outcomes of TURBT treatment, with tumors in the anterior wall and bladder dome showing poor post-TURBT prognosis. Compared to TURBT treatment, partial cystectomy improves the prognosis for bladder dome tumors. This study provides guidance for personalized treatment and prognosis management for NMIBC patients.
大多数膀胱癌是非肌肉浸润性膀胱癌(NMIBC),经尿道膀胱肿瘤切除术(TURBT)是标准治疗方法。然而,术后复发仍然是一个重大挑战,肿瘤位置对预后的影响尚不清楚。本研究旨在探讨肿瘤位置如何影响接受 TURBT 的 NMIBC 患者的预后,并确定最佳手术方法。
进行了一项多中心研究,包括来自 15 家医院(1996-2019 年)的中国 NMIBC 数据和来自 Surveillance, Epidemiology, and End Results(SEER)数据库的 17 个登记处(2000-2020 年)的数据。分析了最初诊断为 NMIBC 并接受 TURBT 或部分膀胱切除术的患者,排除失访或数据缺失的病例。本研究调查了不同肿瘤位置患者的总生存率(OS)、疾病特异性生存率(DSS)和无复发生存率(RFS)。采用 Kaplan-Meier、Cox 回归和倾向评分匹配方法探讨肿瘤位置与预后的关系。进行分层人群分析以尽量减少偏倚。
本研究纳入了 118477 例 NMIBC 患者,结果表明肿瘤位置是影响 TURBT 后预后的重要因素。前壁和穹窿部肿瘤在两个队列中均独立预测不良结局。对于前壁肿瘤,中国队列的 OS 风险比(HR)为 4.35(P<0.0001);RFS HR 为 2.21(P<0.0001);SEER 队列 OS HR 为 1.10(P=0.0001);DSS HR 为 1.13(P=0.0183)。穹窿部肿瘤也显示出类似的趋势[中国 NMIBC 队列 OS HR 为 7.91(P<0.0001);RFS HR 为 2.12(P<0.0001);SEER OS HR 为 1.05(P=0.0087);DSS HR 为 1.14(P=0.0006)]。与标准 TURBT 治疗相比,部分膀胱切除术显著改善了穹窿部肿瘤患者的生存(P<0.01)。
本研究揭示了肿瘤位置在 NMIBC 患者中的重要性,前壁和膀胱穹窿部肿瘤的 TURBT 后预后较差。与 TURBT 治疗相比,部分膀胱切除术改善了膀胱穹窿部肿瘤的预后。本研究为 NMIBC 患者的个体化治疗和预后管理提供了指导。